E-LIB Suche - Ergebnisse für: Schrieber, Sarah J.

1

Evaluation of Truncated AUC as an Alternative Measure to As..:

Wen, Ya‐Feng ; Ji, Ping ; Schrieber, Sarah J....
The Journal of Clinical Pharmacology. 63 (2023) 12 - p. 1417-1429 , 2023

Link: https://doi.org/10.1002/..

2

Safety outcomes when switching between biosimilars and refe..:

Herndon, Thomas M. ; Ausin, Cristina ; Brahme, Nina N....
PLOS ONE. 18 (2023) 10 - p. e0292231 , 2023

Link: https://doi.org/10.1371/..

3

Pharmacodynamic Biomarkers for Biosimilar Development and A..:

Florian, Jeffry ; Sun, Qin ; Schrieber, Sarah J....
Clinical Pharmacology & Therapeutics. 113 (2022) 5 - p. 1030-1035 , 2022

Link: https://doi.org/10.1002/..

4

Considerations for Use of Pharmacodynamic Biomarkers to Sup..:

Sheikhy, Morasa ; Schrieber, Sarah J. ; Sun, Qin...
Clinical Pharmacology & Therapeutics. 113 (2022) 1 - p. 71-79 , 2022

Link: https://doi.org/10.1002/..

5

Considerations for Use of Pharmacodynamic Biomarkers to Sup..:

Florian, Jeffry ; Gershuny, Victoria ; Sun, Qin...
Clinical Pharmacology & Therapeutics. 113 (2022) 2 - p. 339-348 , 2022

Link: https://doi.org/10.1002/..

6

Evaluating the Utility of Proteomics for the Identification..:

Hyland, Paula L. ; Chekka, Lakshmi Manasa S. ; Samarth, Deepti P....
Clinical Pharmacology & Therapeutics. 113 (2022) 1 - p. 98-107 , 2022

Link: https://doi.org/10.1002/..

7

Considerations for Use of Pharmacodynamic Biomarkers to Sup..:

Gershuny, Victoria ; Sun, Qin ; Schrieber, Sarah J....
Clinical Pharmacology & Therapeutics. 113 (2022) 1 - p. 80-89 , 2022

Link: https://doi.org/10.1002/..

8

Impact of Switching on Pharmacokinetics of Therapeutic Biol..:

Ji, Ping ; Ren, Yupeng ; Li, Liang...
The Journal of Clinical Pharmacology. 62 (2021) 1 - p. 36-45 , 2021

Link: https://doi.org/10.1002/..

9

The ELISA Detectability and Potency of Pegfilgrastim Decrea..:

Xie, Tao ; Fang, Hui ; Ouyang, Weiming...
Scientific Reports. 10 (2020) 1 - p. , 2020

Link: https://doi.org/10.1038/..

10

Comparability Considerations and Challenges for Expedited D..:

Schrieber, Sarah J. ; Putnam, Wendy S. ; Chow, Edwin Chiu Yuen...
Drugs in R&D. 20 (2020) 4 - p. 301-306 , 2020

Link: https://doi.org/10.1007/..

11

Update on Therapeutic Protein–Drug Interaction: Information..:

Jing, Xing ; Ji, Ping ; Schrieber, Sarah J...
Clinical Pharmacokinetics. 59 (2019) 1 - p. 25-36 , 2019

Link: https://doi.org/10.1007/..

12

Role of Modeling and Simulation in the Development of Novel..:

Wang, Yow-Ming C. ; Wang, Yaning ; Schrieber, Sarah J....
Journal of Pharmaceutical Sciences. 108 (2019) 1 - p. 73-77 , 2019

Link: https://doi.org/10.1016/..

13

Advancing Biosimilar Development Using Pharmacodynamic Biom..:

Li, Junyi ; Florian, Jeffry ; Campbell, Elizabeth...
Clinical Pharmacology & Therapeutics. 107 (2019) 1 - p. 40-42 , 2019

Link: https://doi.org/10.1002/..

14

Considerations for Biologic Product Drug–Drug Interactions:..:

Schrieber, Sarah J. ; Pfuma‐Fletcher, Elimika ; Wang, Xiaofei...
Clinical Pharmacology & Therapeutics. 105 (2019) 6 - p. 1332-1334 , 2019

Link: https://doi.org/10.1002/..

15

Quantitative Relationship Between AUEC of Absolute Neutroph..:

Li, Liang ; Ma, Lian ; Schrieber, Sarah J....
Clinical Pharmacology & Therapeutics. 104 (2018) 4 - p. 742-748 , 2018

Link: https://doi.org/10.1002/..